NCT04621513

Brief Summary

In this project,the investigators aim to establish a Collaborative Care Model of TCM and Western Medicine to improve the quality of life and symptoms of AR with OSA children and educate care-givers diet and massage information to improve self-care ability and alleviate anxiety for parents. In addition, the investigators will use portable oxymeter to detect the change of SpO2 and respiratory arousal index daily at home and evaluate sensitivity and specificity of portable oxymeter device applied in OSA. The investigators want to give holistic health care for participants and care-givers by this project. In addition, the investigators will build a training environment to provide medical education and training opportunity to teach medical students and clinician the knowledge of pediatric allergic rhinitis and obstructive sleep apnea by caring patients and learning from clinical cases.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 29, 2020

Completed
Same day until next milestone

Study Start

First participant enrolled

July 29, 2020

Completed
3 months until next milestone

First Posted

Study publicly available on registry

November 9, 2020

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 16, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

November 9, 2020

Status Verified

November 1, 2020

Enrollment Period

1.4 years

First QC Date

July 29, 2020

Last Update Submit

November 3, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • The change of mean score of Obstructive Sleep Apnea-18 Questionnaire

    Evaluation quality of life pediatric Obstructive Sleep Apnea-18 ,(score:0-108)

    8 weeks

Secondary Outcomes (8)

  • The change of mean score of Sinus and Nasal Quality of Life Survey

    8 weeks

  • The change of mean score of Pediatric Sleep Questionnaire

    8 weeks

  • The change of mean score of SNAP IV ( Swanson, Nolan and Pelham questionnaire)

    8 weeks

  • Apnea-Hypopnea Index

    8 weeks

  • adeonid nasopharnygeal ratio

    8 weeks

  • +3 more secondary outcomes

Study Arms (2)

Collaborative Care Model of TCM and WM

EXPERIMENTAL

Traditional Chinese Medicine(TCM):laser acupuncture and massage education. Western Medicine (WM):intra-nasal corticosteroid with singulair

Device: laser acupuncture (RJ laser S/N 1813458)Drug: western medicine

Western medicine

ACTIVE COMPARATOR

Western Medicine (WM):intra-nasal corticosteroid with singulair

Drug: western medicine

Interventions

use a low-level-laser acupuncture on acupoint

Collaborative Care Model of TCM and WM

Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD

Also known as: intra-nasal corticosteroid(AVAMYS) with Montelukast (singulair)
Collaborative Care Model of TCM and WMWestern medicine

Eligibility Criteria

Age6 Months - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age less than 18 years old
  • Patients with persistent, moderate to severe allergic rhinitis who have been diagnosed by ARIA (2014) diagnostic criteria
  • AHI by polysomnography is \>1 and diagnosis with obstructive sleep apnea.

You may not qualify if:

  • Abnormal craniofacial structure and require surgery.
  • Patients with sleep apnea caused by muscular dysplasia of the upper respiratory tract ( eg. cerebral palsy, Down syndrome, and other congenital muscular hypoplasia).
  • Mental or behavioral abnormalities that cannot cooperate with the researcher, such as schizophrenia, depression, suicidal ideation, etc.
  • Allergy to the treatment previously
  • Any disease or organ system dysfunction that may be life-threatening

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China Medical University & Hospital

Taichung, 40447, Taiwan

RECRUITING

MeSH Terms

Interventions

montelukast

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Parallel Randomized controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Division of Chinese Medicine Pediatrics

Study Record Dates

First Submitted

July 29, 2020

First Posted

November 9, 2020

Study Start

July 29, 2020

Primary Completion

December 16, 2021

Study Completion

December 31, 2022

Last Updated

November 9, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations